LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...

ROCKVILLE, MD, USA I June 5, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase ...

Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to ...

SAN DIEGO, CA, USA I June 05, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

BOSTON, MY, USA I June 5, 2025 I Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has ...

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to ...

SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling ...

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases ...

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists – Compounds include a highly potent and selective Phase 1-complete candidate and seven preclinical candidates – ...

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data CHICAGO, IL, USA I June 05, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the ...

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.

SHANGHAI, China and CHICAGO, IL, USA I June 5, 2025 I The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio ...